GTC Biotherapeutics to Webcast Corporate Presentation at the C.E.
Unterberg, Towbin Emerging Growth Life Opportunities Conference
FRAMINGHAM, Mass.--(BUSINESS WIRE)--Jul 5, 2007 - GTC
Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today thatGeoffrey Cox, Ph.D., GTC's Chairman and CEO, is scheduled topresent on Wednesday, July 11, 2007 at 9:00 a.m. during the C.E.Unterberg, Towbin Emerging Growth Life Opportunities Conference.The conference is being held at the Mandarin Oriental Hotel, NewYork, New York from July...
Pieris Progresses Development of its Proprietary Biotherapeutics
Platform: Successful Demonstration of Dual Targeting With
Duocalin(R) Technology
FREISING-WEIHENSTEPHAN, Germany, June 21, 2007 /PRNewswire/ --Pieris AG, a bio-pharmaceutical company developing Anticalins(R), anovel class of targeted human protein therapeutics, announced todaythat its proprietary Duocalin(R) technology has successfullydemonstrated dual targeting potential. Commenting on this development, Dr Andreas Hohlbaum, Director ofScience and Preclinical D...
Protalix BioTherapeutics, Inc. Receives Approval from the FDA to
Initiate a Phase III Clinical Trial of prGCD
Phase III clinical trial may commence shortly CARMIEL, Israel, April 18, 2007 /PRNewswire-FirstCall/ ---Protalix
BioTherapeutics, Inc. today announced that it has receivedwritten notice from the United States Food and Drug Administration(FDA) that it may initiate a Phase III clinical trial in the UnitedStates of its lead product candidate, prGCD, a proprietary plantcell expressed recombin...